Everolimus/Cyclosporine Interactions on Bile Flow and Biliary Excretion of Bile Salts and Cholesterol in Rats

Digestive Diseases and Sciences

Volumn 49, Issue 1, 2004, Pages 30-37

  Deters, Michael ^a   Kirchner, Gabriele ^a   Koal, Therese ^a   Resch, Klaus ^a   Kaever, Volkhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bile flow; Cholestasis; Cyclosporine; Everolimus; Hypercholesterolemia; Rat

Indexed keywords

BILE SALT; CHOLESTEROL; CYCLOSPORIN; CYCLOSPORIN A; DRUG DERIVATIVE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TRIACYLGLYCEROL;

ANIMAL; ANIMAL MODEL; ARTICLE; BILE; BILE DUCT FISTULA; BILE FLOW; BILIARY EXCRETION; BLOOD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IATROGENIC DISEASE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BILE; CHOLESTEROL; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; MALE; RATS; RATS, WISTAR; SIROLIMUS; TRIGLYCERIDES;

EID: 0842291684     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000011598.15105.58     Document Type: Article

References (40)

1. Seghal SN: Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monitor 17:660-665, 1995
2. Liu J, Farmer JD, Lane C, Friedman J, Weissman I, Schreiber S: Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK 506 complexes. Cell 66:807-815, 1991
3. Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64:36-42, 1997
4. Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W: SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64:32-35, 1997
5. Mayer AD, Dmitrewski J, Squiffflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, Van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbolt D, Neumayr HH, Hauser RI, Ericzon BG, Brattström C, Claesson K, Mühlbacher F, Pohanka E: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 64:436-443, 1997
6. Bennett WM, Demattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50:1089-1100, 1996
7. Andoh TF, Burdman EA, Bennett WM: Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 17:34-45, 1997
8. Schuurman HJ, Schuler W, Ringers J, Jonker M: The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30:2198-2199, 1998
9. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M: Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 69:737-742, 2000
10. Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE: Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation 67:956-962, 1999
11. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE: Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 18:150-159, 1999
12. Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)- rapamycin. Transplantation 69:488-496, 2000
13. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE: Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in nonhuman primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 69:76-86, 2000
14. Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U: SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 69:497-502, 2000
15. Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 294:323-332, 2000
16. Bohler T, Waiser J, Budde K, Lichter S, Jauho A, Fritsche L, Korn A, Neumayer HH: The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 30:2195-2197, 1998
17. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 69:48-56, 2001
18. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73:920-925, 2002
19. Dueland S, Reichen J, Everson GT, Davis RA: Regulation of cholesterol and bile acid homeostasis in bile-obstructed rats. Biochem J 280:373-377, 1991
20. Chisholm JW, Nation P, Dolphin PJ, Agellon LB: High plasma cholesterol in drug-induced cholestasis is associated with enhanced hepatic cholesterol synthesis. Am J Physiol 276:G1165-G1173, 1999
21. Deters M, Nolte K, Kirchner G, Resch K, Kaever V: Comparative study analyzing effects of sirolimus-cyclosporin and sirolimustacrolimus combinations on bile flow in the rat. Dig Dis Sci 46:2120-2126, 2001
22. Deters M, Klabunde T, Kirchner G, Resch K, Kaever V: Sirolimus/ cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. Br J Pharmacol 136:604-612, 2002
23. Queneau PE, Bertault-Peres P, Guitaoui M, Mesdjian E, Durand A, Montet JC: Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat. Dig Dis Sci 39:1581-1585, 1994
24. McGowan MW, Artiss JD, Strandbergh DR, Zak B: A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29:538-542, 1983
25. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW: Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075-1080, 1983
26. Mashige F, Tanaka N, Maki A, Kamei S, Yamanaka M: Direct spectrophotometry of total bile acids in serum. Clin Chem 27:13452-13456, 1981
27. Consensus Document: Hawk's Cay meeting on the therapeutic drug monitoring of cyclosporine. Transplant Proc 22:1357-1361, 1999
28. Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF: Liquid chromatographic measurement of cyclosporine A and its metabolites in blood, bile and urine. Clin Chem 34:34-39, 1988
29. Deters M, Kirchner G, Resch K, Kaever V: Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 40:285-292, 2002
30. Stacey NH, Kotecka B: Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology 95:780-786, 1988
31. Mosley RH, Johnson TR, Morrissette JM: Inhibition of bile salt transport by cyclosporine A in rat liver plasma membrane vesicles. J Pharmacol Exp Ther 253:974-980, 1990
32. Böhme M, Müller M, Leier I, Jedlitschky G, Keppler D: Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile sait transport in rat liver. Gastroenterology 107:255-265, 1994
33. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430, 2001
34. Moran D, De Buitrago JM, Fernandez E, Galan AI, Munoz ME, Jimenez R: Inhibition of biliary glutathione excretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug. J Hepatol 29:68-77, 1998
35. Bramow S, Ott P, Nielsen FT, Bangert K, Tygstrup N, Dalhoff K: Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 89:133-139, 2001
36. Al Raves O, Wallmark A, Floren CH: Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydioxy-3- methylglutaryl coenzyme A reductase inhibitors. Hepatology 25:991-994, 1997
37. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey L, Jaffe JS, Oppermann S, Kahan BD, Morrissett JD: Effect of sirolimus on the metabol ism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 72:1244-1250, 2001
38. Graham J, Ahmed H, Northfield TC: Unidirectional pathway of vesicular cholesterol transport. In Trends in Bile Salt Research. G Paumgartner, (ed). Dordrecht, New York, Kluwer, 1989, pp 177-187
39. Napoli KL, Wang ME, Urbauer D, Kahan BD: Comparison of effects of sirolimus (RAPA) and everolimus (RAD) on cyclosporine (CSA) whole blood and tissue concentration in rats. Ther Drug Monit 23:469, 2001
40. Lampen A, Zhang Y, Hackbarth I, Benet LZ Sewing KF, Christians U: Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285:1104-1112, 1998